In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter

Cancer Science

Volumn 103, Issue 9, 2012, Pages 1730-1736

  Momose, Isao ^a   Tatsuda, Daisuke ^a   Ohba, Shun ichi ^a   Masuda, Tohru ^a   Ikeda, Daishiro ^a   Nomoto, Akio ^a  

^a INSTITUTE OF MICROBIAL CHEMISTRY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; FLUORESCENT DYE; GREEN FLUORESCENT PROTEIN; ORNITHINE DECARBOXYLASE; PROTEASOME; UNCLASSIFIED DRUG; ZSPROSENSOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG POTENCY; FEMALE; FLUORESCENCE; FLUORESCENCE MICROSCOPE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE; FEMALE; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; MICE; MICE, NUDE; MOLECULAR IMAGING; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865718679     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02352.x     Document Type: Article

References (27)

1. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996; 65: 801-47.
2. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999; 68: 1015-68.
3. Maki CG, Howley PM. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 1997; 17: 355-63.
4. Pagano M, Tam SW, Theodoras AM et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682-5.
5. Ciechanover A, DiGiuseppe JA, Bercovich B et al. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci USA 1991; 88: 139-43.
6. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78: 773-85.
7. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003; 100: 9946-51.
8. Fribley A, Zeng Q, Wang CY et al. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004; 24: 9695-704.
9. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 417-21.
10. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-60.
11. Adams J, Behnke M, Chen S et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998; 8: 333-8.
12. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-22.
13. Richardson PG, Briemberg H, Jagannath S et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113-20.
14. Lonial S, Waller EK, Richardson PG et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106: 3777-84.
15. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-17.
16. Ludwig H, Khayat D, Giaccone G, Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005; 104: 1794-807.
17. Luker GD, Pica CM, Song J, Luker KE, Piwnica-Worms D. Imaging 26S proteasome activity and inhibition in living mice. Nat Med 2003; 9: 969-73.
18. Williamson MJ, Blank JL, Bruzzese FJ et al. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Mol Cancer Ther 2006; 5: 3052-61.
19. Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol 2000; 18: 538-43.
20. Rickardson L, Wickström M, Larsson R, Lövborg H. Image-based screening for the identification of novel proteasome inhibitors. J Biomol Screen 2007; 12: 203-10.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
22. Momose I, Sekizawa R, Hashizume H et al. Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. I. Taxonomy, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo) 2001; 54: 997-1003.
23. Murakami Y, Matsufuji S, Kameji T et al. Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature 1992; 360: 597-9.
24. Orlowski RZ, Stinchcombe TE, Mitchell BS et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420-7.
25. Chauhan D, Catley L, Li G et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8: 407-19.
26. Piva R, Ruggeri B, Williams M et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008; 111: 2765-75.
27. Kupperman E, Lee EC, Cao Y et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010; 70: 1970-80.